Treatment of Tac-Expressing Cutaneous T-Cell Lymphoma (CTCL) and Adult T-Cell Leukemia (ATL) With Yttrium-90 Radiolabeled Anti-Tac - Related Studies

Treatment of Tac-Expressing Cutaneous T-Cell Lymphoma (CTCL) and Adult T-Cell Leukemia (ATL) With Yttrium-90 Radiolabeled Anti-Tac

This study has been completed.

Study NCT00001249. Last updated on March 3, 2008. Information provided by National Institutes of Health Clinical Center (CC)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Leukemia, T-Cell
		Lymphoma, T-Cell, Cutaneous

2	Additional conditions recognized in this trial
		Leukemia
		Leukemia-Lymphoma, Adult T-Cell
		Lymphoma
		Lymphoma, T-Cell
		Mycosis Fungoides
		Sezary Syndrome

3	More general conditions related to this trial
		Immune System Diseases
		Immunoproliferative Disorders
		Leukemia, Lymphoid
		Lymphatic Diseases
		Lymphoma, Non-Hodgkin
		Lymphoproliferative Disorders
		Neoplasms
		Neoplasms by Histologic Type

4	Additional drug interventions recognized in this trial
		Daclizumab

5	More general drug interventions related to this trial
		Immunologic Factors
		Immunosuppressive Agents
		Pharmacologic Actions
		Physiological Effects of Drugs

6	Sponsors listed in this trial
		National Cancer Institute (NCI)